Amgen Inc. (NASDAQ: AMGN) announced it will expand its direct-to-patient program AmgenNow to include two additional medications at discounted prices, according to a company statement.
The biotechnology company said it will offer Aimovig and Amjevita through the program at $299 per month, representing price reductions of nearly 60% and 80% below their current U.S. list prices, respectively. The program launched in October 2025 with Repatha available at $239 monthly, about 60% below its list price.
AmgenNow serves patients who are uninsured, enrolled in high-deductible health plans, or prefer to pay out of pocket. All three medicines will also be available through TrumpRx.gov, the company stated.
"The U.S. leads the world in biopharmaceutical innovation, and we look forward to continued engagement with the U.S. government to see that this innovation is appropriately supported globally," said Robert A. Bradway, chairman and chief executive officer at Amgen.
The company said the action satisfies components outlined in a July 31 letter from President Trump, including Most Favored Nation pricing requests, though additional details remain confidential.
Amgen reported it has invested more than $40 billion in manufacturing and research and development since 2018. The company announced an additional $2.5 billion in U.S. manufacturing capital investments this year, including $900 million in Ohio and $1 billion in North Carolina expansions.
In recognition of continued investments, Amgen will receive relief from industry-specific tariffs for three years, the company stated. The investments were facilitated by the Tax Cuts and Jobs Act of 2017 and the One Big Beautiful Bill Act of 2025, according to the statement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.